AstraZeneca AZN announced today that Gaithersburg, Md., will be one of
three global research and development centers to improve pipeline productivity
and to establish the company as a global leader in biopharmaceutical
innovation. Additionally, US-based global marketing and specialty care
commercial functions will be centered in Gaithersburg, currently the site of
MedImmune's headquarters and the primary location for AstraZeneca's biologics
activities.
The relocation of research and development, global marketing and specialty
care positions from Wilmington will be carried out through 2015. The North
America commercial headquarters, along with several corporate-based support
functions, will remain in Wilmington.
The changes are part of AstraZeneca's announcement to invest in strategic
research and development centers in Cambridge, UK; Gaithersburg, Md.; and
Mölndal, Sweden. The proposals are designed to co-locate teams to improve
collaboration and put science and the patient at the heart of everything the
company does. The changes will also simplify the company's global site
footprint.
The consolidation of AstraZeneca's global R&D footprint will have an impact on
sites in the United States. About 1,200 positions will leave Wilmington, while
there will be an increase of about 300 positions in Gaithersburg. The changes
announced today will lead to an estimated overall reduction of about 650
positions in the US, while around 170 will relocate to other AstraZeneca sites
in the US or overseas.
AstraZeneca will provide an update on its business strategy and implementation
plans at its Investor Day presentation on Thursday, March 21.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in